Navigation Links
URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
Date:1/8/2009

The University of Rochester Medical Center (URMC) has received a U.S. patent for a diagnostic technology that can rapidly and accurately screen for organisms such as bacteria and other infectious agents. Lighthouse Biosciences, LLC, a Rochester-based life sciences company, is the exclusive worldwide license holder of the technology.

The company's technology platform called NanoLantern is a novel method of identifying genetic sequences from biological samples, a process that can be used to detect any organism or genetic feature by identifying its unique DNA fingerprint. The NanoLantern consists of an array of DNA probes that can be programmed from a database of known genetic signatures to simultaneously screen for multiple individual targets using a single sample of blood, urine, cells, or other substance with organic content. The U.S. patent is being awarded for the process the technology uses to identify DNA sequences. The method, first developed by University of Rochester scientists in 2003, promises to be faster and more precise than other existing models.

"This patent represents an important milestone in developing the company's intellectual property portfolio," said Rand Henke, CEO of Lighthouse Biosciences. "It addresses a breakthrough method that will allow the company to design and make at a low cost a very wide range of probes for the detection of most pathogens."

The company is in the process of developing a prototype that consists of a series of disposable biosensor cartridges or labs on a chip that will be housed in a workstation that can be deployed in hospitals, doctor's offices, nursing homes, or any other health care setting.

While the technology has a wide array of potential applications in healthcare, agriculture, food safety, water quality, and national security, Lighthouse Biosciences is initially focused on the field of hospital-acquired infections (HAI). HAI are infections that patients receive during their care in a hospital or other health care facility such as a nursing home that are not related to any pre-existing medical condition. Despite extensive efforts in recent years to address the causes, HAI remain a massive burden on the U.S. health care system with more than 1 million annual cases and 90,000 associated deaths, all at a healthcare cost of $5.7 billon per year and at a cost to society of approximately $30 billion per year in the U.S.

One of the key challenges in combating HAI is the need to develop a system of surveillance that can identify these infections as early as possible. The current standard is to send potentially infectious samples out to a clinical laboratory for analysis and wait for the results. This process typically takes up to 2 to 3 days depending upon the proximity of the lab to the health care facility and the speed at which the lab can process the samples, a delay that can be an impediment to successful treatment. The NanoLantern technology has demonstrated the ability to provide results rapidly within 15 minutes and do so at the point of care.

The largest category of HAIs is urinary tract infections, which account for 40% of all infections. Lighthouse Biosciences, in cooperation with the URMC Departments of Urology and Microbiology and Immunology is currently conducting clinical studies to test the screening system at URMC's Strong Memorial Hospital.

The underlying technology for the company's NanoLantern platform was first developed by University of Rochester scientists Benjamin Miller, Ph.D., Todd Krauss, Ph.D. and Christopher Strohsahl, Ph.D. In addition to faculty appointments at the University, all three also hold corporate positions and/or equity positions in the company. Lighthouse Biosciences L.L.C., which was founded by the scientists in 2005, is based in the Lennox Tech Enterprise Center in Henrietta.


'/>"/>

Contact: Mark Michaud
mark_michaud@urmc.rochester.edu
585-273-4790
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. URMC, FDA to collaborate on national data repository for heart research
2. Position Statement Regarding Lt. Gov. Paterson from Tara A. Cortes, Ph.D, RN President and CEO of Lighthouse International
3. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
4. CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform
5. Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus
6. Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance
7. Cell Biosciences Introduces First Protein Analysis Kits
8. Catalyst Biosciences Appoints Dr. Todd Lorenz Chief Medical Officer
9. Magellan Biosciences Companies to Feature Diagnostic Products Designed to Improve Health Outcomes at the Clinical Lab Expo
10. Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies
11. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology: